Cytosorbents Crp (CTSO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cytosorbents Crp stock (CTSO) is currently trading at $0.70. Cytosorbents Crp PS ratio (Price-to-Sales) is 1.12. Analyst consensus price target for CTSO is $5.25. WallStSmart rates CTSO as Sell.
- CTSO PE ratio analysis and historical PE chart
- CTSO PS ratio (Price-to-Sales) history and trend
- CTSO intrinsic value — DCF, Graham Number, EPV models
- CTSO stock price prediction 2025 2026 2027 2028 2029 2030
- CTSO fair value vs current price
- CTSO insider transactions and insider buying
- Is CTSO undervalued or overvalued?
- Cytosorbents Crp financial analysis — revenue, earnings, cash flow
- CTSO Piotroski F-Score and Altman Z-Score
- CTSO analyst price target and Smart Rating
Cytosorbents Crp
📊 No data available
Try selecting a different time range
Smart Analysis
Cytosorbents Crp (CTSO) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Cytosorbents Crp (CTSO) Key Strengths (1)
Paying $1.12 for every $1 of annual revenue
Supporting Valuation Data
Cytosorbents Crp (CTSO) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 4.6x book value
Low institutional interest, mostly retail-driven
Solid revenue growth at 10.10% per year
Cytosorbents Crp (CTSO) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 8.0/10) while 7 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales. Valuation metrics including Price/Sales (1.12) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Book (4.61) suggest expensive pricing. Growth concerns include Revenue Growth at 10.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -93.30%, Operating Margin at -28.10%, Profit Margin at -27.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -93.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 10.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CTSO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CTSO's Price-to-Sales ratio of 1.12x trades at a deep discount to its historical average of 37.68x (1th percentile). The current valuation is 100% below its historical high of 832.25x set in Dec 2014, and 2% above its historical low of 1.1x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~1.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cytosorbents Crp (CTSO) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Cytosorbents Crp is in a turnaround phase, with management focused on restoring profitability. Revenue reached 37M with 10% growth year-over-year. The company is currently unprofitable, posting a -27.8% profit margin.
Key Findings
The company is unprofitable with a -27.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Cytosorbents Crp.
Bottom Line
Cytosorbents Crp is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Cytosorbents Crp(CTSO)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Cytosorbents Corporation, a critical care focused immunotherapy company, is dedicated to the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. The company is headquartered in Monmouth Junction, New Jersey.